Difference between revisions of "Team:Kyoto/Safety"
| Line 33: | Line 33: | ||
</ul></li><li><a href="https://2017.igem.org/Team:Kyoto/Notebook">Notebook</a></li><li><a href="https://2017.igem.org/Team:Kyoto/integrated">Practice</a> | </ul></li><li><a href="https://2017.igem.org/Team:Kyoto/Notebook">Notebook</a></li><li><a href="https://2017.igem.org/Team:Kyoto/integrated">Practice</a> | ||
<ul> | <ul> | ||
| − | <li><a href="https://2017.igem.org/Team:Kyoto/ | + | <li><a href="https://2017.igem.org/Team:Kyoto/Human_Practices">Human Practice</li> |
| − | <li><a href="https://2017.igem.org/Team:Kyoto/ | + | <li><a href="https://2017.igem.org/Team:Kyoto/Integrated_Practices">Integrated Human Practice</li> |
| − | <li><a href="https://2017.igem.org/Team:Kyoto/ | + | <li><a href="https://2017.igem.org/Team:Kyoto/Engagement">Public Engagement</li> |
<li><a href="https://2017.igem.org/Team:Kyoto/Collaborations">Collaboration</li> | <li><a href="https://2017.igem.org/Team:Kyoto/Collaborations">Collaboration</li> | ||
</ul></li><li><a href="https://2017.igem.org/Team:Kyoto/Team">Team</a> | </ul></li><li><a href="https://2017.igem.org/Team:Kyoto/Team">Team</a> | ||
| Line 43: | Line 43: | ||
</ul></li><li><a href="https://2017.igem.org/Team:Kyoto/Safety">Safety</a></li> | </ul></li><li><a href="https://2017.igem.org/Team:Kyoto/Safety">Safety</a></li> | ||
</ul> | </ul> | ||
| − | + | </header> | |
| + | |||
<h1>About Safety</h1> | <h1>About Safety</h1> | ||
<ul class="Safety"> | <ul class="Safety"> | ||
Revision as of 15:31, 28 October 2017
About Safety
1) Safe project design
Rev, a protein which we used for nuclear export of mRNA, derives from HIV-1. Although HIV-1 is known for cause of AIDs (Acquired immunedeficiency syndrome), this protein does not cause any diseases.
2) Safe lab work
We did all experiments using the safety and management manual we made by ourselves.
Three of us recieved safety lecture in Kyoto University and shared it.
